{
  "id": 8364880,
  "title": "Kestra Medical (KMTS) Raises Outlook. Can Better Reimbursement Support Scale?",
  "url": "https://urgent.news/2026/09/17/kestra-medical-kmts-raises-outlook-can-better-reimbursement-support",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-17T21:14:16.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/kestra-medical-kmts-raises-outlook-211416393.html"
  },
  "original_language": "en",
  "account": "Kestra Medical Technologies, Ltd. (KMTS) boosted its fiscal first-quarter 2027 revenue by 60% to $31.0 million, driven by growth in the wearable cardioverter defibrillator market, competitive share gains, new sales territories, an increased proportion of in-network patients, and improvements in revenue cycle management. Gross margin rose to 56.5%, up from 45.7%, indicating a 98% increase in gross profit compared to a 46% increase in GAAP operating expenses. The company expects $141 million in revenue for the full fiscal year, up 48% year-over-year. However, the expanding organization still consumes more than it generates in gross profit, leading to a widening GAAP operating loss to $37.7 million from $28.9 million. Cash outflows rose to $32.3 million, while cash, equivalents, and investments totaled $244.7 million, down from $262.2 million. While KMTS is improving its commercial economics, the decisive test will be whether additional gross-profit dollars consistently exceed additional operating expenses.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}